-

Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Contacts

Investors:
Caroline Corner
investors@personalis.com
415-202-5678

Media:
pr@personalis.com

Industry:

Personalis, Inc.

NASDAQ:PSNL
Release Versions
English

Contacts

Investors:
Caroline Corner
investors@personalis.com
415-202-5678

Media:
pr@personalis.com

More News From Personalis, Inc.

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have obtained Class A CE-IVD marking in compliance with the European Union’s In Vitro Diagnostic Regulation (IVDR). The CE Mark represents an important regulatory milestone, ensuring that clinical trial sites throughout the European Union and Great Britain can use these col...

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with NeXT Per...

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that six clinical abstracts demonstrating the broad use of its NeXT Personal® test will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 to June 2 in Chicago. Highlights include an oral podium presentation from the landmark TRACERx study, which demonstrates the clinical impact of NeXT Personal’s single-d...
Back to Newsroom